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ABSTRACT
Objectives: To describe our screening population and audit of the performance of first-trimester screening for Down 
syndrome, based on a combined test, enhanced with additional ultrasound markers, over the whole period of the study.
Material and methods: We performed a prospective study from 2009 to 2016, which included 1358 singleton fetuses with 
a crown-rump length of 45–84 mm. The risk of aneuploidy was calculated using nuchal translucency, fetal heart rate (FHR), 
and additional markers, such as nasal bone (NB), tricuspid flow (TF) and ductus venosus (DV), combined with maternal 
serum free β-human chorionic gonadotropin (fβ-hCG) and pregnancy-associated plasma protein-A (PAPP-A). 
Results: 87% of patients were evaluated using all the additional ultrasound markers and 97% of patients were assessed 
using at least two markers, in any combination. 70.5% of patients were also evaluated using maternal serum biochemistry. 
The most common risk calculation used nuchal translucency, FHR, all additional ultrasound markers, fβ-hCG and PAPP-A in 
851 (62.7%) of cases. The adjusted risk of trisomy 21 was greater than 1:100 in 65 (4.8%) women. Of these patients, 58 (87.7%) 
chose to have an invasive test. There were 24 aneuploid fetuses (1.7%); and from these we identified 12 (50%) trisomy 21, 
6 (25%) sex chromosome anomalies, with the remainder being triploidy and trisomy 18/13. The combined test detected 
11 of the 12 cases as having trisomy 21, with a first trimester detection rate of 91.7%. 39 fetuses (2.8%) had various types 
of structural anomalies. 
Conclusion: The combined test enhanced with all additional ultrasound markers did not show any substantial improve-
ment in T21 detection rate, when compared with using only one of the additional markers. 
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INTRODUCTION
Screening for chromosomal and structural anomalies at 
the end of the first trimester of pregnancy has developed 
rapidly in the last decade and is now important in prenatal 
consultation. It evolved as a combination of considering ma-
ternal age, fetal nuchal translucency (NT) thickness, maternal 
serum free β-human chorionic gonadotropin (β-hCG) and 
pregnancy associated plasma protein-A (PAPP-A) at 11–13 we-
eks’ gestation [1]. Usually, the accuracy of the screening is 
increased by assessing additional ultrasound markers, such as 
the nasal bone (NB) [2], the tricuspid flow (TR) [3], the ductus 
venosus flow (DV) [4] and the fetal heart rate (FHR) [5].
The screening algorithm was developed by the Fetal Medi-
cine Foundation (FMF) [6] and is known as the combined first 
trimester test. It uses an a priori aneuploidy risk derived from 
maternal age and maternal history, multiplied by likelihood 
ratios resulting from the deviation of the measured individual 
values from the respective expected median [7]. It was valida-
ted in large prospective studies and its simplest form, combi-
ning NT and maternal biochemistry, can detect 90% of trisomy 
21 (T21) affected pregnancies at a false-positive rate (FPR) of 
about 5% [5, 8]. A positive consequence of screening for T21 is 
the early diagnosis of trisomies 18 and 13, which are the second 
and third most common chromosomal abnormalities [9]. 
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When the combined screening test is enhanced with 
one of the additional ultrasound markers such as NB, TR 
or DV, the T21 detection rate improves to 91–96%, while 
reducing the FPR to about 2.5% [6, 10]. Few studies have 
examined the screening performance when all additional 
markers are assessed together. Using an ultrasound only 
based protocol, with NT and all additional markers, for a FPR 
of 5%, the detection rate for T21 reached 94–97.5% [11–13]. 
When all of these markers were added to a traditional com-
bined test, the detection rate substantially increased to up 
to 100%, for a FPR of 2.4% [14] or 3.4% [15].
The aim of our study was to describe the screening 
population and to audit the performance of a first-trime-
ster combined test, enhanced with additional ultrasound 
markers, in 1358 prospectively examined singleton pregnan-
cies. Our hypothesis was that the screening performance 
would be like that estimated by the original model and 
observed in other large studies.
MATERIAL AND METHODS
The data for our study resulted from the clinical imple-
mentation of a combined test in screening for aneuploidies 
at 11 to 13 weeks’ gestation in women with singleton pre-
gnancies, with a crown-rump length of 45–84 mm, who 
attended our Fetal Medicine Centre (private practice), from 
January 2009 to December 2016. Written informed consent 
was obtained from each patient and the study followed the 
principles of the Declaration of Helsinki. 
Fetal evaluation was realized prospectively, according to 
the FMF protocol for combined first trimester test screening 
for trisomy 21 [8]. The ultrasound scans were done transab-
dominally (or transvaginal if needed) to estimate the gesta-
tional age through the measurement of the fetal crown-rump 
length (CRL) and to diagnose any major fetal anomalies [16]. 
NT thickness was measured at the time of the examina-
tion, together with an evaluation of all additional (seconda-
ry) first trimester ultrasound markers (NB, TR, DV, FHR) if this 
was technically possible [3]. All scans were performed by 
FMF certified operators, who passed an annual audit based 
on the distribution of their NT measurements (www.fetalme-
dicine.org), using mainly Voluson E8 but also E6 and 730 (GE 
Medical Systems, Zipf, Austria) ultrasound machines. We 
followed the ALARA (As Low As Reasonably Achievable) 
principle for acoustic power and our output data was within 
the limits already described [17].
Samples of maternal blood for biochemistry screening 
were collected at 9 to 14 weeks, depending on the time of 
patients’ counselling sessions. Concentrations of PAPP-A and 
free b-hCG were measured by external laboratories using 
the Cobas (Roche, Switzerland), Delfia Express (Perkin Elmer, 
USA), Immulite (Siemens AG, Germany) or Kryptor (Brahms 
AG, Germany) systems. 
Finally, the risks of aneuploidies were calculated using 
the FMF algorithm embedded in Astraia software (Astraia, 
Germany), which was updated in consecutive versions.
The results of the tests were explained to the parents. Wo-
men with a calculated risk of carrying a fetus with trisomy 
21 equal to, or greater than, 1 in 100 were defined ‘high risk’ 
and had the option of an invasive procedure such as cho-
rionic villi sampling (CVS) or amniocentesis. Also, the risk of 
aneuploidies was considered high if atrioventricular septal 
defects, holoprosencephaly, exomphalos, diaphragmatic 
hernia or megacystis were found on the scan. The parents 
were informed about the low risk of miscarriage associated 
with the invasive procedures. Women who wished to have 
an invasive test, despite their risk being considered low, 
were not denied this. Low risk patients were reassured that 
trisomies were unlikely and no further testing was offered. 
Together with those who refused further invasive testing, 
they received routine antenatal care and we followed up on 
the outcome of their pregnancy. 
The main genetic testing that was offered was a rapid 
analysis of chromosomes 21, 18, 13, X and Y through FISH 
or QF-PCR together with karyotyping. Genetic testing re-
sults were entered in the electronic database, whenever 
available. We performed a follow up on the outcomes of 
patients’ pregnancies.
Patient characteristics, test results and pregnancy out-
comes were obtained from the Astraia database, genetic lab 
records and direct questioning of the parents.
Descriptive data were presented in median and range, 
for continuous variables, and in numbers and percentages 
for categorical variables. Comparisons between categorical 
variables were by Fisher’s exact test. We used the statistical 
software package SPSS 23.0 (SPSS Inc., Chicago, IL) for data 
analyses.
RESULTS
We screened 1358 women with singleton pregnancies 
at 11–13 weeks by ultrasonography, during an eight-year 
study period. We found a continuous increase in patients’ 
addressability, and the number of patients scanned annually 
increased by 220% by the end of the study. To our know-
ledge, this study is one of the largest populations whose 
first-trimester screening data has been analysed in our area.
The ethnicity of patients was mostly Caucasian (99.9%) 
and 310 (22.8%) of the women were aged 35 years or older. 
The median maternal age was 31 years (range, 16 to 44 years) 
(Fig. 1). The median BMI was 22.5 (range, 14.8 to 39.1) and the 
median maternal weight was 62 kg (range, 38 to 114 kg). The 
median CRL was 61 mm (range, 45 to 84 mm, imposed by 
design). The median gestational age at the time of ultrasound 
evaluation was 12+3 weeks (range, 10 + 5 to 14 + 6 weeks). 
1259 women (92.7%) were non-smokers. Conception was 
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spontaneous in 1296 (95.4%) of the pregnancies, by assisted 
reproductive technology in 53 (3.9%) and not recorded in 
9 (0.66%). Among the 1338 pregnant women there were 
18 (1.3%) who had had a prior pregnancy with a chromoso-
mal anomaly, 12 (67%) of which had been Down syndrome. 
All 1358 fetuses had an ultrasound exam with NT me-
asurement and in 401 (29.5%) the risk calculation was based 
only on ultrasound data. The most common associations of 
ultrasound markers for risk assessment were respectively: 
NT, FHR, NB, TR and DV in 1181 (87%) cases; NT, FHR, DV and 
TR in 82 (6%) cases; NT, FHR, NB and TR in 33 (2.4%) cases; and 
NT, FHR, NB and DV in 21 (1.5%) cases (Tab. 1). The fetal risk 
assessment using NT and all additional ultrasound markers 
had a relatively stable frequency during the study period, 
with annual values ranging from 80% to 91%. Also, the as-
sociation of NT measurement with at least two additional 
markers was done in 1317 (97%) cases, exhibiting a stable 
annual frequency from 94% to 99%.
The NT measurements met the FMF criteria: normal 
distribution of the NT deviation from the expected me-
dian for CRL measurements, 57.3% of NT values greater 
than the median and 6.9% greater than the 95th percentile. 
The 33 fetuses (2.4%) had a NT > 3.5 mm (99th percentile).
In 957 (70.5%) of the women, the trisomy 21 risk was 
assessed through the first trimester combined test. We 
found a tremendous increase in the acceptability of the 
combined test during the first three years of our study, 
with the acceptability figures stabilizing at 84-89% in the 
last 5 years. In 720 (75.2%) cases, maternal blood sampling 
was performed at the time of, or after, the ultrasound exam, 
two thirds of them within two days of the ultrasound. The 
median gestational age at the time of the biochemistry test 
was 12.3 weeks (range, 9 + 3 to 14 + 2 weeks). 
In the range of combined tests performed, the most 
common combination of risk calculations was based on 
the assessment of NT, FHR, NB, TR, DV, fβ-hCG and PAPP-A, 
namely in 851 (89%) of cases; the next most commonly 
used combinations of markers was NT, FHR, DV, TR, fβ-hCG 
and PAPP-A in 50 (5.2%) cases; followed by NT, FHR, NB, TR, 
fβ-hCG and PAPP-A in 22 (2.3%) cases; and NT, FHR, NB, DV, 
fβ-hCG and PAPP-A in 13 (1.4%) cases. Overall, the associa-
tion of NT measurement with at least two additional markers 
and biochemistry was found in 936 (97.8%) cases (Tab. 1). 
From all women with an ultrasound ± biochemical scre-
ening in first trimester, 65 (4.8%) had a calculated risk of 
trisomy 21 greater than 1 in 100, which is the screen positive 
Table 1. First trimester screening for trisomy 21 based on maternal age, fetal NT and different combinations of additional sonographic markers, 
associated or not with maternal serum biochemistry
With biochemistry No biochemistry Total
NT + all US markers 851 (88.9) 330 (82.3) 1181 (87.0)
NT + 2 US markers 85 (8.9) 51 (12.7) 136 (10.0)
NT + 1 US marker 11 (1.1) 16 (4.0) 27 (2.0)
NT 10 (1.0) 4 (1.0) 14 (1.0)
Data are given as n (%); NT — nuchal translucency; US — ultrasound
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Figure 1. Maternal age distribution of the study population, in years
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rate. 58 of the 65 (87.7%) women with high risk chose to have 
an invasive test and the rest chose not to have any further 
testing. In the high-risk group, we performed 51 CVS and 
10 amniocenteses. Of the 7 non-tested patients, one had 
an undetected trisomy 21, three opted for pregnancy ter-
mination because of associated major fetal malformations, 
two were normal at birth and one removed themselves from 
the study. Also, some patients with a calculated risk of less 
than 1 in 100 elected to have invasive testing. 
Overall, 92 of fetuses (6.8%) from our first trimester po-
pulation were evaluated through an invasive procedure: CVS 
and amniocentesis. With the low-risk patients, the closer 
their results were to the 1 in 100 risk margin, the more likely 
they were to choose to have a diagnostic procedure (Fig. 2). 
In the last years of our study, some women from low- or 
intermediate-risk groups chose to have an analysis of cell 
free fetal DNA of the maternal blood.
There were 24 aneuploid fetuses in our population 
(1.7%): 12 cases of trisomy 21, 3 cases of trisomy 18, 3 cases 
of triploidy, 4 cases of monosomy X, and 2 other numerical 
anomalies of sex chromosomes. 
Based on the maternal age distribution and the age-
-related risk at 12 weeks’ gestation, the expected number 
of trisomy 21 in our study population was 6, which was not 
significantly different from the observed number of trisomy 
21 (Fisher exact test, p = 0.165). All cases with Down’s syndro-
me had a calculated risk for trisomy 21 of between 1:2 and 1:4. 
The combined test enhanced with ultrasound markers 
detected 11 of the 12 cases of trisomy 21, with a first trime-
ster detection rate (DR) of 91.7%. The missed trisomy 21 was 
one of our first series’ cases and the abnormal ductus venous 
flow was not recognized. Then, at 30 weeks the fetal scan de-
monstrated growth restriction and several anomalies. The 
final diagnosis was made at birth. 
39 fetuses (2.8%) had these types of structural anoma-
lies: ventriculomegaly, holoprosencephaly, acrania, cleft 
lip/palate, diaphragmatic hernia, gastroschisis, omphaloce-
le, hydrops, megacystis, and limb abnormalities. Overall, we 
found 1.2% (17 cases) of the fetuses had major heart defects.
DISCUSSION
In this paper we present the population characteristics 
and the results from our implementation of the combined 
test enhanced with additional ultrasound markers, at 11 to 
13 + 6 weeks’ in a private center. Overall, 87% of patients in 
the study had an evaluation of all additional markers (NB, 
DV, TR) and in 97% at least two markers were assessed, in 
any combination. 70% of patients were also evaluated using 
maternal serum biochemistry. In our population, the detec-
tion rate for trisomy 21 was high, at 91.7% with a FPR of 4.8%.
When comparing the standard combined test, our results 
were found to be similar to both those from the most recent 
prospective multicenter study of Nicolaides and col. [8] (92% 
DR for a FPR of 4.6%), and the original model study [5] (90% DR 
for a FPR of 3%). Two other recent studies also reported similar 
detection rates [18, 19] of 91.6% and 93.75%, respectively.
When we compare our results with those from studies 
that used a combined test enhanced by all additional ultra-
sound markers, we achieved the same detection rate as that 
published by Karadzov-Orlic et al. [20] (93% DR for FPR of 
4.8%), at a cutoff of 1:275. However, we failed to reach the 
excellent 100% detection rates obtained by Hsiao et al. [14] or 
Ghaffari et al. [15] at lower FPRs of 2.4% or 3.4%, respectively.
Our results were at the same DR, but with a lower FPR 
than those found by studies which used an ultrasound-ba-
sed protocol (NT and all additional markers). Thus, at a 5% 
FPR, Abele et al. [13] reached a DR for T21 of 97.5%, while 
Wiechec et al. [11, 12] achieved a DR of 94–95%. 
Figure 2. Frequency of invasive procedures (columns) and mean risk value (line) per groups of 50 women, ordered by trisomy 21 adjusted 
risk, descending. Patients with an adjuster risk for trisomy 21 and 18 greater than 1 in 100 were excluded
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Finally, our T21 detection rate was much higher than that 
of the triple test, which has been found to be around 70%, 
and higher than that of the quadruple test, which has 
an overall detection rate of approximately 80% [21, 22]. 
When compared with second trimester maternal serum 
tests, the first trimester combined test achieves a better 
detection rate and provides an earlier diagnosis. Therefore, 
we demonstrated the usefulness of the first trimester com-
bined test in Down syndrome screening.
Our median maternal age was 31 years, which was com-
parable to other values registered in Spain (32.4 years in 
2016) [23], Romania (29.6 years in 2017) [18, 24] or in Poland 
(34 years in 2017) [19], for first-trimester screening population.
Our patients were quite slim, with a median BMI of 22.5, 
which favored the incorporation of all additional first trime-
ster ultrasound markers into the screening. Overall, we in-
corporated at least two additional markers in the screening 
of 97% of patients. 
We found an increased acceptability of the combined 
test instead versus ultrasound first-trimester screening only, 
especially in the last 5 years of the study, when 84–98% of 
the patients accepted maternal serum screening. This is 
remarkable, in conditions when all screening investigations 
undertaken at the patients’ own cost. However, we acknow-
ledge that the biochemical component of the combined test 
has only recently been covered by public health insurance 
(namely, from 2015, the last but one year of the study), and 
that the FMF-certified biochemistry machines were either 
not available in the first years or the costs were high; so, 
many patients preferred not to pay directly for serum te-
sting and others were not particularly interested in a more 
accurate risk assessment for aneuploidies.
Eighty eight percent of the women with positive scre-
ening results opted to have further invasive diagnostic te-
sting. No miscarriages were reported. However, other patients 
from both the intermediate- and low-risk groups also elected 
to have the invasive procedure. With the low-risk patients, the 
closer their results were to the 1 in 100 risk margin, the more 
likely they were to choose to have a diagnostic procedure 
(Fig. 2). Thus, at a mean adjusted risk for trisomy 21 of 1 in 
400, 25% of the women chose to have a diagnostic procedure. 
The percentage dropped exponentially, so, at 1 in 1000, only 
10% elected to have an invasive test. These figures could in 
the future be lowered further through the availability of cell 
free fetal DNA analysis of the maternal blood [25].
The small sample size of our study, in comparison with lar-
ger prospective studies, could be a weakness, and associated 
with the small number of T21 cases in our study, could have 
lowered the detection rate. In addition, because the study 
was conducted in a single private center, the result cannot 
fully represent the screening performance across our whole 
population, due to the possibility of selection bias. Moreover, 
the overall screening performance might be affected by the 
test timing [26]. Also, the study was limited with regard to the 
diagnosis of other chromosomal anomalies, because the main 
genetic test was a rapid analysis of chromosomes 21, 18, 13, 
X and Y through FISH or QF-PCR. The test was offered free of 
charge in the final 4 years of our study as the costs were re-
imbursed by health assurance. The frequency of karyotyping 
prior to this, was therefore low, because of the costs.
CONCLUSIONS
The purpose of our study was to provide information 
on the screening performance of first-trimester combined 
testing and on the population characteristics in a private 
medical center. We compared the results with those of We-
stern countries and with different screening methodologies. 
The detection rate and FPR of the first trimester scre-
ening conducted in our medical center were comparable 
with others that had been reported previously. A combined 
test enhanced with all additional ultrasound markers did not 
show any substantial improvement in T21 detection rates 
compared with using only one of the additional markers as 
recommended by FMF. In our conditions, this early screening 
method can improve detection rates without increasing 
invasive procedures and can detect some early major fetal 
anomalies. Finally, our data shows that the combined first 
trimester test for aneuploidies is a robust test, providing 
an effective and reliable screening.
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